Abstract: The invention provides an oromucosal film composition comprising: a therapeutically effective amount of epinephrine solid particles having a particle size in the range of from about 0.01 um to about 100 um; and a pharmaceutically acceptable polymer wherein the epinephrine solid particles are dispersed in and/or disposed on a polymeric layer. The film compositions can be used for the treatment of anaphylactic shock, cardiac arrest, asthma, bronchial asthma, bronchitis, emphysema, respiratory infections, and allergic reactions. The film compositions may further contain local anesthetics and used for providing local anesthesia, such as for the treatment or prevention of tooth pain and treatment of mouth ulcers.

Abstract: The invention provides an oromucosal film composition comprising: a therapeutically effective amount of one or more active pharmacutical ingredients selected from the group consisting of fluticasone, liraglutide, glucagone, midazolam, diazepam, lidocaine, articaine, bupivacaine, prilocaine, mepivacaine, epinephrine and salts thereof; a pharmaceutically acceptable polymer; and an absorption enhancer selected from the group consisting of diethylene glycol monoethyl ether, eugenol, bile acids, caprylocaproyl polyoxyl-8 glycerides, disodium ethylenediaminetetraacetic acid, salt and mixtures thereof, wherein the composition comprises at least diethylene glycol monoethyl and eugenol as absorption enhancers when it comprises epinephrine alone or together with one or more of lidocaine, articaine, bupivacaine, prilocaine, mepivacaine as active pharmacutical ingredients.

Abstract: The invention provides an oromucosal film composition comprising: a therapeutically effective amount of epinephrine solid particles having a particle size in the range of from about 0.01 um to about 100 um; and a pharmaceutically acceptable polymer wherein the epinephrine solid particles are dispersed in and/or disposed on a polymeric layer. The film compositions can be used for the treatment of anaphylactic shock, cardiac arrest, asthma, bronchial asthma, bronchitis, emphysema, respiratory infections, and allergic reactions. The film compositions may further contain local anesthetics and used for providing local anesthesia, such as for the treatment or prevention of tooth pain and treatment of mouth ulcers.

Abstract: New aminooxylipids of general formula I, wherein n1=5-30 and X is polymethylene linker of the general formula II where n2=2-10, or X is polyethylene glycol linker of the general formula III, wherein n3=1-14 are provided. A method of preparation of the aminooxylipids of general formula I characterized in that the acylation of N-tert-butoxycarbonyl-polymethylenediamine {(CH3)3C—O—(C?O)—HN—(CH2)n—NH2, n=2-13}, or N-tert-butoxycarbonyl-polyethyleglycoldiamine {(CH3)3C—O—(C?O)—HN—(CH2)2—[O—(CH2)]n—O—(CH2)2NH2, n=1-14} with in position C(2) symmetrically branched fatty acids of general formula IV, wherein n1=5-30, in the presence of condensation reagent, or from acid of general formula IV derived acylchloride of general formula V wherein n1=5-30, produces N-Boc-aminolipids of general formula VI, wherein n1=5-30 a X is polymethylene linker of the general formula II or X is polyethylene glycol linker of the general formula III.

Abstract: New aminooxylipids of general formula I, wherein n1=5-30 and X is polymethylene linker of the general formula II where n2=2-10, or X is polyethylene glycol linker of the general formula III, wherein n3=1-14 are provided. A method of preparation of the aminooxylipids of general formula I characterized in that the acylation of N-tert-butoxycarbonyl-polymethylenediamine {(CH3)3C—O—(C?O)—HN—(CH2)n—NH2, n=2-13}, or N-tert-butoxycarbonyl-polyethyleglycoldiamine {(CH3)3C—O—(C?O)—HN—(CH2)2—[O—(CH2)]n—O—(CH2)2NH2, n=1-14} with in position C(2) symmetrically branched fatty acids of general formula IV, wherein n1=5-30, in the presence of condensation reagent, or from acid of general formula IV derived acylchloride of general formula V wherein n1=5-30, produces N-Boc-aminolipids of general formula VI, wherein n1=5-30 a X is polymethylene linker of the general formula II or X is polyethylene glycol linker of the general formula III.

Abstract: The present invention relates to a mucoadhesive carrier system, for particles, which comprises nanoscaffold having a nanofibrous layer with a thickness of from 0.1 to 1000 ?m, carrying a substance in the form of particles. The mucoadhesive layer, in at least a part of its surface, overlaps the nanoscaffold. A process for its preparation and its use for delivery of the vaccines and therapeutics to mucosal surfaces is also disclosed.